Acquired Hemophilia A and B as an initial manifestation of Non-Hodgkin Lymphoma. Case report and literature review
DOI:
https://doi.org/10.35509/01239015.93Keywords:
Acquired Hemophilia, Hemophilia A, Hemophilia B, LymphomaAbstract
Acquired hemophilia is a potentially fatal rare complication of patients with hematological malignancies (usually lymphoproliferative disorders) or solid tumors. We report a 75-year female patient with a history of arterial hypertension and iron deficiency anemia. Log in to the emergency department complaining of generalized cramping abdominal pain associated with emetic episodes and melenic stools. In initial studies found prothrombin time (PT) 19 seconds control: 11 seconds, INR 1.8 and activated partial thromboplastin time (aPTT) 45 seconds, control: 29 seconds. Mixing aPTT study with normal plasma was performed suggesting specific anticoagulation factor. Other tests were performed: Factor IX 0%, factor VIII and 0%. Factor VIII inhibitor: 180 UB, factor IX inhibitor: 130 UB. It was considered acquired hemophilia A and B and was studying with extension studies found a splenic marginal non Hodgkin lymphoma.
References
Giangrande P. Acquired Hemophilia. Revised edition. World Federation of Hemophilia. 2012;(38) [internet]. Available in: http://www1.wfh.org/publications/files/pdf-1186.pdf
Knoebl P, Marco P, Baudo F, Collins P, Hüth-Kuhne A, Nemes L, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622-31.
Seethala S, Collins NP Jr, Comerci G Jr. An Unusual Etiology for Elevation of Activated Partial Thromboplastin Time (aPTT) in SLE: Acquired Hemophilia and Lupus Anticoagulant. Case Rep Hematol. 2013;2013:521785.
Hay CR. Acquired haemophilia. Baillière’s Clin Haematol. 1998;11(2):287-303.
Reeves BN, Key NS. Acquired hemophilia in malignancy. Thromb Res. 2012;129 Suppl 1:S66-8.
Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemos. 1981;45(3):200-3.
Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemos. 1997;78(6):1463-7.
Yee TT, Taher A, Pasi KJ, Lee CA. A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period. Clin Lab Haematol. 2000;22(5):275-8.
Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Bri J Haemotol. 2003;121(1):21-35.
Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007; 109(5):1870-7.
Bitting RL, Bent S, Li Y, Kohlwes J. The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis. Blood Coagul Fibrinolysis. 2009;20(7):517-23.
Seethala S, Barnes K, Corral J. Acquired factor VIII inhibitor: a rare etiology for bruisability and anemia. Indian J Hematol Blood Transfus. 2013;29(3):178-80.
Kamal A, Tefleri A, Pruthi, R. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc. 2007;82(7):864-73.
Remotti L, Grosso SH, Ingratti MF, Vera MP, Woods A, Sánchez-Luceros A, et al. Inhibidores adquiridos de la coagulación: enfoque diagnóstico y casos especiales. Acta Bioquím Clin Latinoam. 2016;50(2):291-301.
Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost. 1987; 57(2):144-7.
Tcherniantchouk O, Laposata M, Marques MB. The isolated prolonged PTT. Am J Hematol. 2013;88(1):82-5.
Oh J, Lim Y, Jang MJ, Huh JY, Shima M, Oh D. Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A. Blood Res. 2013;48(1):58-62.
Jedidi I, Hdiji S, Ajmi N, Makni F, Masmoudi S, Elloumi M, et al. Acquired haemophilia B: a case report and literature review. Ann Biol Clin (Paris). 2011;69(6):685-8.
Miller K, Neely JE, Krivit W, Edson JR. Spontaneously acquired factor IX inhibitor in a nonhemophiliac child. J Pediatr. 1978;93(2):232-4.
Mazzucconi MG, Peraino M, Bizzoni L, Bernasconi S, Luciani M, Rossi GD. Acquired inhibitor against factor IX in a child: successful treatment with high-dose immunoglobulin and dexamethasone. Haemophilia. 1999;5(2):132-4.
Largo R, Sigg P, von Felten A, Straub PW. Acquired factor-IX inhibitor in a nonhaemophilic patient with autoimmune disease. Br J Haematol. 1974;26(1):129-40.
Berman BW, McIntosh S, Clyne LP, Goldberg B, Lobel J, Komp DM. Spontaneously acquired Factor IX inhibitors in childhood. Am J Pediatr Hematol Oncol. 1981;3(1):77-81.
Collins PW. Therapeutic challenges in acquired factor VIII deficiency. Hematology Am Soc Hematol Educ Program. 2012;2012:369-74.
Lian EC, Villar MJ, Noy LI, Ruiz-Dayao Z. Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone. Am J Hematol. 2002;69(4):294-5.
Zeitler H, Ulrich-Merzenich G, Panek D, Goldmann G, Vidovic N, Brackmann HH, et al. Extracorporeal treatment for the acute and long-term outcome of patients with life-threatening acquired hemophilia. Transfus Med Hemother. 2012;39(4):264-70.
Kasper C. Diagnosis and Management of Inhibitors to Factors VIII and IX. An Introductory Discussion for Physicians. Treatment of Hemophilia: World Federation of Hemophilia, 2004.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
